{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T06:17:06Z","timestamp":1788675426209,"version":"build-2803163510"},"reference-count":16,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T00:00:00Z","timestamp":1739491200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:p>Recent advances in immunotherapy have significantly improved outcomes for cancer patients. However, therapies such as immune checkpoint inhibitors (ICIs) can lead to immune-related adverse events, including potentially fatal ICI-myocarditis. The diagnosis of ICI-myocarditis is complex, and cardiac MRI plays a crucial role in identifying this condition. This report presents a novel finding of elevated muscular T1 and T2 relaxation parameters using standard CMR sequences, correlating with the clinical progression of ICI-myotoxicity affecting not only the heart but also the skeletal thoracic muscles and the diaphragm. Identifying diaphragm involvement in these patients is particularly important, as it may result in respiratory failure. MRI has shown significant potential in assessing diaphragmatic function, as well as detecting tissue damage and edema, while also monitoring their evolution over time. This comprehensive, imaging-based approach could guide treatment decisions, including the use of corticosteroids and immunosuppressive therapies. Combining functional and non-invasive tissue assessments in a single MRI examination may enhance early diagnosis and improve the management of patients undergoing ICI therapy.<\/jats:p>","DOI":"10.3389\/fcvm.2025.1527048","type":"journal-article","created":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T06:59:56Z","timestamp":1739516396000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Case Report: Immune checkpoint-inhibitor related myotoxicity monitoring using a comprehensive cardiothoracic MRI approach: insights from a clinical case"],"prefix":"10.3389","volume":"12","author":[{"given":"Samia","family":"Boussouar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Etienne","family":"Charpentier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baptiste","family":"Abbar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesus","family":"Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Similowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathieu","family":"Kerneis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yves","family":"Allenbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Bretagne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joe Elie","family":"Salem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alban","family":"Redheuil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,2,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1801214","DOI":"10.1183\/13993003.01214-2018","article-title":"ERS statement on respiratory muscle testing at rest and during exercise","volume":"53","author":"Laveneziana","year":"2019","journal-title":"Eur Respir J"},{"key":"B2","doi-asserted-by":"publisher","first-page":"5139","DOI":"10.1007\/s00330-019-06054-6","article-title":"Comparison of MR T1 and T2 mapping parameters to characterize myocardial and skeletal muscle involvement in systemic idiopathic inflammatory myopathy (IIM)","volume":"29","author":"Huber","year":"2019","journal-title":"Eur Radiol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"e004699","DOI":"10.1136\/jitc-2022-004699","article-title":"Reversal of immune-checkpoint inhibitor fulminant myocarditis using personalized-dose-adjusted abatacept and ruxolitinib: proof of concept","volume":"10","author":"Nguyen","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1016\/S1470-2045(18)30608-9","article-title":"Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study","volume":"19","author":"Salem","year":"2018","journal-title":"Lancet Oncol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1001\/jamacardio.2021.2241","article-title":"Clinical strategy for the diagnosis and treatment of immune checkpoint inhibitor-associated myocarditis: a narrative review","volume":"6","author":"Lehmann","year":"2021","journal-title":"JAMA Cardiol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1148\/radiol.2021210814","article-title":"Cardiac MRI depicts immune checkpoint inhibitor-induced myocarditis: a prospective study","volume":"301","author":"Faron","year":"2021","journal-title":"Radiology"},{"key":"B7","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1093\/ehjacc\/zuac129","article-title":"The new 2022 ESC guidelines on cardio-oncology and their impact on the acute cardiovascular care society","volume":"11","author":"von Kemp","year":"2022","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"B8","doi-asserted-by":"publisher","first-page":"e012459","DOI":"10.1161\/CIRCIMAGING.121.012459","article-title":"Multiparametric early detection and prediction of cardiotoxicity using myocardial strain, T1 and T2 mapping, and biochemical markers: a longitudinal cardiac resonance imaging study during 2 years of follow-up","volume":"14","author":"Giusca","year":"2021","journal-title":"Circ Cardiovasc Imaging"},{"key":"B9","doi-asserted-by":"publisher","first-page":"7657","DOI":"10.1007\/s00330-022-08844-x","article-title":"The prognostic value of global myocardium strain by CMR-feature tracking in immune checkpoint inhibitor-associated myocarditis","volume":"32","author":"Zhao","year":"2022","journal-title":"Eur Radiol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1161\/CIRCULATIONAHA.118.034497","article-title":"Myocarditis in the setting of cancer therapeutics: proposed case definitions for emerging clinical syndromes in cardio-oncology","volume":"140","author":"Bonaca","year":"2019","journal-title":"Circulation"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1016\/j.jacc.2021.01.050","article-title":"Myocardial T1 and T2 mapping by magnetic resonance in patients with immune checkpoint inhibitor-associated myocarditis","volume":"77","author":"Thavendiranathan","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1002\/ejhf.3340","article-title":"Cardiovascular toxicities of immune therapies for cancer - a scientific statement of the heart failure association (HFA) of the ESC and the ESC council of cardio-oncology","volume":"26","author":"Tocchetti","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"B13","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1007\/s11886-022-01680-x","article-title":"State-of-the-art of endomyocardial biopsy on acute myocarditis and chronic inflammatory cardiomyopathy","volume":"24","author":"Ammirati","year":"2022","journal-title":"Curr Cardiol Rep"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1016\/j.cjca.2020.12.022","article-title":"Immune checkpoint inhibitor myocarditis with normal cardiac magnetic resonance imaging: importance of cardiac biopsy and early diagnosis","volume":"37","author":"Ederhy","year":"2021","journal-title":"Can J Cardiol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.jacc.2019.11.049","article-title":"Global longitudinal strain and cardiac events in patients with immune checkpoint inhibitor-related myocarditis","volume":"75","author":"Awadalla","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"e0246764","DOI":"10.1371\/journal.pone.0246764","article-title":"Left ventricular myocardial strain and tissue characterization by cardiac magnetic resonance imaging in immune checkpoint inhibitor associated cardiotoxicity","volume":"16","author":"Higgins","year":"2021","journal-title":"PLoS One"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2025.1527048\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T06:59:58Z","timestamp":1739516398000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2025.1527048\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,14]]},"references-count":16,"alternative-id":["10.3389\/fcvm.2025.1527048"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2025.1527048","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,14]]},"article-number":"1527048"}}